SOURCE: Erchonia

Erchonia | Laser Healthcare

October 06, 2010 09:00 ET

Erchonia Secures Zerona Distribution in South East Asia

Recent FDA Approval Kicks Off International Expansion

MCKINNEY, TX--(Marketwire - October 6, 2010) -  Erchonia, the global leader in low level laser therapy applications, today announces the launch of the Zerona® body-contouring laser in South East Asia's SAARC. Erchonia Asia will exclusively market and sell the Zerona throughout the region. This new expansion coincides with the recent U.S. FDA-approval of the Zerona Laser, a non-invasive, painless treatment that guarantees the removal of fat.

"We are certain Zerona's research, development and proven efficacy combined with our local market knowledge will ensure the tremendous success of this launch," says Dr. Anoop Chaturvedi, CEO of Erchonia Asia. "The recent FDA approval for Zerona has triggered expansion opportunities and opened up an entire market for developing countries."

"We welcome Dr. Chaturvedi to the Erchonia Worldwide distribution network and look forward to working together to bring our life-changing technology to the people of South East Asia," adds Steve Shanks, President of Erchonia.

The Zerona protocol consists of six treatments; one forty-minute treatment every other day for two weeks. Zerona is the only device on the market to prove its efficacy through a double blind, multi-site, placebo controlled study, and is the only non-invasive procedure that guarantees an average of three inches lost in as little as two weeks.

In pilot studies, Zerona has been shown to increase sensitivity to the hunger-hormone leptin. This sensitivity decreases patients' appetite, helping them modify their diet and portion choices going forward.

In contrast to high-power and high-heat lasers, Erchonia's Zerona produces a low-level output that has no thermal effect on the body's tissue. Unlike the majority of other devices on the market, its unique technology does not kill or damage fat cells but instead creates a pore in each cell for the fat to leak out of and be processed naturally through the lymphatic system. Zerona is the first painless body sculpting procedure to effectively remove excess fat without harming the fat cell.

Zerona's external application provides results without the dangers associated with invasive weight loss surgery. The Zerona procedure is painless, has no downtime and no negative side effects, allowing patients to remain active during treatment.

For more information, please visit or

About Erchonia Asia
Erchonia Asia is a subsidiary of AVI Pharma Pvt. Ltd., an independent entrepreneurial trading company which has exclusive licensing distribution rights for Erchonia products for the SAARC countries in South East Asia. Its mission is to enable South East Asian patients' access to therapies based on Low Level Laser Therapy technologies. For additional information, visit